TannerCares supported an employee-led hurricane relief effort in Jamaica, bringing together teams across Tanner to deliver essential supplies, coordinate logistics, and provide direct support to communities impacted by the storm.

Tanner Pharma Group has been recognised as one of the Charlotte Business Journal’s Best Places to Work, reflecting a culture shaped by collaboration, shared purpose, and a commitment to improving access to medicines worldwide.

Jonathan Bracey shares his son George’s experience with an ultra-rare disease, highlighting the challenges families face and the importance of collaboration, research, and access in advancing care.

Tanner Pharma Group and UCB Pharma have initiated a partnership in Southeast Asia to support access to innovative epilepsy treatments for patients across the region.

Tanner Pharma Group has expanded its US operations with a new facility in Charlotte, enhancing its capabilities in clinical trial support, secondary packaging, and global distribution.

Tanner Pharma has partnered with Agenus to expand global access to investigational immunotherapies through a Named Patient Program for patients with advanced cancers.

Tanner Pharma Group has been recognized as one of the Charlotte Business Journal’s Best Places to Work, reflecting a culture shaped by collaboration, shared purpose, and a commitment to improving access to medicines worldwide.

This contribution, made through Tanner’s philanthropic arm, TannerCares , was inspired by Tanner EVP Jonathan Bracey’s young son George, who has been facing a rare form of cancer, rhabdomyosarcoma, since 2023. We encourage you to read more about George’s incredible journey here.

Tanner Pharma Group and Nephcentric LLC have signed a global distribution agreement enabling TannerGAP to provide access to ure-Na (Urea 15g) in international markets outside the US, Canada, and the Middle East where it is not yet registered, expanding availability for patients in need.

The partnership between Tanner Pharma and The Max Foundation is a story of dedication to making the world a better place. For over a decade, we have collaborated to provide vital medicines to people facing life-threatening diseases. Our shared mission is to break down barriers and provide global access to treatment for all in need.

Our Annual Charity Golf Day at Redbourn Golf Club is not just a day on the green; it's a day of camaraderie and making an impact. This year's event was truly special, and we're happy to share a few highlights.

Azienda Farmaceutica Italiana (“AFI”), an Italian pharmaceutical company and innovator in therapeutic solutions and new treatment possibilities, and TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, have entered into a license agreement for the distribution of Hepilor® in Latin America.

Treeapp is a global tree planting and carbon offsetting organisation, planting trees on 80+ sites across the world, spanning 13 different countries across 4 continents. Tanner and Treeapp have been working together since February 2022.

In response to the ongoing crisis in Ukraine, Tanner Pharma Group will contribute over $124,500 and donate 14,803 units of essential products to select organizations that are making a positive impact and actively providing direct aid and relief.

Tanner Pharma Group , an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe.

Oneness Biotech, a leading biotech company listed on the Taipei stock exchange, and Tanner Pharma UK Limited (“Tanner Pharma”), a specialist pharmaceutical services provider of medicine access solutions, announced the initiation of an early access program for Fespixon in Europe, the UK, Russia, Latin America, the Middle East and North Africa (MENA) where Fespixon is not commercially available.

Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a global Named Patient Program for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of diabetic macular edema (DME) and in Europe and the Middle East, for the treatment of non-infectious posterior uveitis (NIU-PS).

Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.

Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited ("TannerLAC"), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro diagnostic test in the Latin American region.

Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries.